News
ICLR
185.27
-0.09%
-0.16
ICON (ICLR) Stock Still Looks Undervalued Following A 35% Five Year Fall
Simply Wall St · 13h ago
Is ICON (ICLR) A Bargain Following Strong Bookings And Backlog?
Simply Wall St · 2d ago
How Strong Bookings At ICON (ICLR) Has Changed Its Investment Story
Simply Wall St · 3d ago
DaVita Inc. Stock Slips 6.2%, Underperforms Peers
Dow Jones · 5d ago
DaVita Inc. stock underperforms Tuesday when compared to competitors
MarketWatch · 5d ago
Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF), Icon (ICLR) and Shattuck Labs (STTK)
TipRanks · 5d ago
ICON plc (ICLR) Executive Moves to Dismiss Securities Fraud Claims, Citing No Statements and Lack of Jurisdiction
TipRanks · 6d ago
Weekly Report: what happened at ICLR last week (1012-1016)?
Weekly Report · 10/19 09:07
RBC Capital Keeps Their Buy Rating on Icon (ICLR)
TipRanks · 10/12 11:45
Weekly Report: what happened at ICLR last week (1005-1009)?
Weekly Report · 10/12 09:07
ICON (ICLR) Trades Below Fair Value, Can Growth Rebuild Confidence?
Simply Wall St · 10/11 05:29
ICON upgraded at BofA on better CRO demand, improved 2027 visibility
Seeking Alpha · 10/09 19:22
Icon upgraded to Neutral from Underperform at BofA
TipRanks · 10/09 11:50
ICON plc Sets Dates for Third-Quarter 2026 Earnings Release and Call
TipRanks · 10/08 12:48
Barclays Keeps Their Hold Rating on Icon (ICLR)
TipRanks · 10/07 08:06
RBC Capital Sticks to Its Buy Rating for Icon (ICLR)
TipRanks · 10/07 01:48
Weekly Report: what happened at ICLR last week (0928-1002)?
Weekly Report · 10/05 09:07
'HHS launches project to speed up clinical trials' - Axios
Benzinga · 09/30 19:17
Icon Price Target Announced at $195.00/Share by UBS
Dow Jones · 09/30 12:55
UBS Reinstates Neutral on Icon, Announces $195 Price Target
Benzinga · 09/30 12:45
More
Webull provides a variety of real-time ICLR stock news. You can receive the latest news about ICON plc through multiple platforms. This information may help you make smarter investment decisions.
About ICLR
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.